BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nakada H, Takashima K. Where Can Patients Obtain Information on the Preapproval Access Pathway to Investigational Treatment in Japan? A Survey of Patient Advocacy Organizations' Websites. Clin Pharmacol Drug Dev 2019;8:978-83. [PMID: 31592580 DOI: 10.1002/cpdd.745] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Borysowski J, Górski A. ClinicalTrials.gov as a Source of Information About Expanded Access Programs: Cohort Study. J Med Internet Res 2021;23:e26890. [PMID: 34709189 DOI: 10.2196/26890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Borysowski J, Górski A. Public availability of results of ClinicalTrials.gov-registered expanded access studies. Br J Clin Pharmacol 2021. [PMID: 33971033 DOI: 10.1111/bcp.14890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Borysowski J, Górski A. ClinicalTrials.gov as a Source of Information About Expanded Access Programs: Cohort Study (Preprint).. [DOI: 10.2196/preprints.26890] [Reference Citation Analysis]
4 Borysowski J, Górski A. Ethics framework for treatment use of investigational drugs. BMC Med Ethics 2020;21:116. [PMID: 33208140 DOI: 10.1186/s12910-020-00560-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Nakada H, Folkers KM, Takashima K. Comparative Assessment of Non-trial Access to Investigational Medical Products in the U.S. and Japan. Ther Innov Regul Sci 2021;55:401-7. [PMID: 33098080 DOI: 10.1007/s43441-020-00228-x] [Reference Citation Analysis]